JP2008540554A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540554A5
JP2008540554A5 JP2008511312A JP2008511312A JP2008540554A5 JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5 JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5
Authority
JP
Japan
Prior art keywords
halo
group
hydrogen atom
alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540554A (ja
JP5089578B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/018061 external-priority patent/WO2006124447A2/en
Publication of JP2008540554A publication Critical patent/JP2008540554A/ja
Publication of JP2008540554A5 publication Critical patent/JP2008540554A5/ja
Application granted granted Critical
Publication of JP5089578B2 publication Critical patent/JP5089578B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008511312A 2005-05-13 2006-05-10 選択的なアンドロゲン受容体調節物質としての置換型n−アリールピロリジン Expired - Fee Related JP5089578B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68091105P 2005-05-13 2005-05-13
US60/680,911 2005-05-13
PCT/US2006/018061 WO2006124447A2 (en) 2005-05-13 2006-05-10 Substituted n-arylpyrrolidines as selective androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2008540554A JP2008540554A (ja) 2008-11-20
JP2008540554A5 true JP2008540554A5 (enExample) 2009-06-25
JP5089578B2 JP5089578B2 (ja) 2012-12-05

Family

ID=37057376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511312A Expired - Fee Related JP5089578B2 (ja) 2005-05-13 2006-05-10 選択的なアンドロゲン受容体調節物質としての置換型n−アリールピロリジン

Country Status (17)

Country Link
US (1) US7807691B2 (enExample)
EP (1) EP1891038B1 (enExample)
JP (1) JP5089578B2 (enExample)
CN (1) CN101175747B (enExample)
AT (1) ATE412647T1 (enExample)
AU (1) AU2006247738A1 (enExample)
BR (1) BRPI0610183A2 (enExample)
CA (1) CA2608419A1 (enExample)
CY (1) CY1108690T1 (enExample)
DE (1) DE602006003432D1 (enExample)
DK (1) DK1891038T3 (enExample)
ES (1) ES2314922T3 (enExample)
MX (1) MX2007014053A (enExample)
PL (1) PL1891038T3 (enExample)
PT (1) PT1891038E (enExample)
SI (1) SI1891038T1 (enExample)
WO (1) WO2006124447A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617256C (en) * 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AU2008284662B2 (en) 2007-08-07 2013-07-25 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター(sarm)およびその使用
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009133861A1 (ja) * 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
AU2012220572A1 (en) * 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2014078778A2 (en) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
SG11202011135WA (en) 2018-05-14 2020-12-30 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114746400A (zh) * 2019-11-20 2022-07-12 南京明德新药研发有限公司 用作选择性雄激素受体调节剂的化合物
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2025160286A1 (en) * 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MXPA05001631A (es) 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
WO2004037784A2 (en) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
JP2007500245A (ja) * 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物

Similar Documents

Publication Publication Date Title
JP2008546791A5 (enExample)
JP2017526677A5 (enExample)
JP2006151984A5 (enExample)
RU2502730C2 (ru) Сульфонамидные соединения и их применение
JP2009523760A5 (enExample)
JP2006528597A5 (enExample)
HRP20210291T1 (hr) Imunoregulatorna sredstva
JP2005523922A5 (enExample)
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
JP2018519245A5 (enExample)
JP2018516238A5 (enExample)
JP2011527334A5 (enExample)
JP2013056886A5 (enExample)
JP2011504903A5 (enExample)
JP2007508361A5 (enExample)
SI1902026T1 (sl) Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
JP2014505107A5 (enExample)
JP2020502116A5 (enExample)
SE0402925D0 (sv) Novel Compounds
JP2017525717A5 (enExample)
CY1111744T1 (el) Τροποποιητες της δραστηριοτητας toy υποδοχεα χημειοκινων, κρυσταλλικες μορφες και διεργασια
JP2010539091A5 (enExample)
RU2009111387A (ru) Фармацевтические композиции для лечения грибковых инфекций